Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant leuprorelin after radical prostatectomy in high‑risk prostate cancer
2010-022037-29Phase 3Active
- Sponsor
- Unicancer
- Start
- Nov 2010
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of leuprolide in prostate adenocarcinoma and prostate cancer (PCa) (2 arms), sponsored by Unicancer. Primary endpoint: Metastasis-free survival at 10 years. Started Nov 2010; status: active.
02
Drugs
leuprolide
03
Conditions
prostate adenocarcinomaprostate cancer (PCa)
Beyond the preview
Go deeper on 2010-022037-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022037-29.